Skip to main content

Sequenom Closes $130M Notes Offering

NEW YORK (GenomeWeb News) – Sequenom said after the close of the market Monday that it has completed the private placement of $130 million of 5 percent convertible senior notes due 2017.

The San Diego-based molecular diagnostics firm said the placement included $20 million aggregate principal amount of notes from the full exercise of the over-allotment option.

Net proceeds from the offering will be used to fund further commercialization of Sequenom's MaterniT21 Plus non-invasive test for trisomies, 21, 18, and 13.

The notes placement follows a public offering of Sequenom common stock earlier this year that brought in $62 million in gross proceeds.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.